Information Provided By:
Fly News Breaks for October 1, 2015
ENDP, AMGN, ALXN, CELG
Oct 1, 2015 | 06:28 EDT
Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth peers that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer tells investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." He expects large-cap biopharma companies to lift the sector out of the recent weakness. His preferred growth names include Celgene (CELG), Alexion (ALXN), Amgen (AMGN) and Endo (ENDP).
News For CELG;ALXN;AMGN;ENDP From the Last 2 Days
There are no results for your query CELG;ALXN;AMGN;ENDP